MolecuLight Wins Point-of-Care Wound Imaging Devices Agreement with Premier, Inc.


Efficient June 1, 2022the new contract allows Premier members, at their discretion, to take advantage of Premier pre-negotiated pricing and special terms for MolecuLight’s point-of-care wound imaging devices under the Skin Integrity product category.

MolecuLight imaging devices are the only FDA cleared devices that allow clinicians to visualize the presence, location and load of bacteria (>104 CFU/g) in wounds in real time. Published results from a recent clinical trial of 350 patients and 14 sites showed that the clinical standard of care alone detected 15% of wounds with high bacterial load, while the addition of the MolecuLight device led to an improvement 400% in the detection of these wounds2. Presence of high bacterial loads are known to impede wound healing1 and removal of bioburden is key to improving wound outcomes1. The I:X and DX provide invaluable bacterial information at the point of care to inform clinical decision making and enable targeted wound treatments. In a recent study, the incorporation of bacterial information from MolecuLight imaging resulted in a 23% increase in wound healing rates, while decreasing the use of antimicrobials and antibiotics3. MolecuLight devices also perform accurate digital wound measurement, enabling consistent wound monitoring and documentation.

“We are delighted to have entered into a supply agreement with Premiere and honored that our MolecuLight point-of-care devices have received the award. Technological breakthrough designation“, says Anil Amlani, CEO of MolecuLight. “Thanks to the I:X and DX, we hope to enable significant cost savings and improved clinical outcomes. Premier’s vast membership base can now easily access MolecuLight wound imaging devices and see the clinical benefits in their wound care practices. »

In addition to clinical benefits, MolecuLight procedures performed in United States may benefit from availability way of reimbursement including two CPT® codes for the doctor’s work to be performed”fluorescence imaging for bacterial presence, location and load » procedures and ease of payment for Hhospital Oambulatory Dapartment (HOPD) and Aambulatory Surgical VSWalk in (CSA) parameters via a Aambulatory Ppayment VSclassification (APC) assignment.

1 Caldwell et al. Surg Clin North Am2020, 100(4)
The et al. Advanced Wound Care, 2021
3Price et al. Diagnosis, 2020

About MolecuLight Corp.

MolecuLight Corp. is the American subsidiary of MolecuLight Inc., a privately held medical imaging company that has developed and commercializes its proprietary fluorescent imaging platform technology in multiple clinical markets. The suite of released MolecuLight devices, including the MolecuLight I: and DX™ and their accessories, provide portable point-of-care imaging devices for the global real-time wound care market detection of wounds containing high bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with unmet needs globally, including food safety, consumer cosmetics and other key industrial markets.

Attached and uploaded to

SOURCE MolecuLight


Comments are closed.